The number of chikungunya cases in the UK has surged by 170%, with 73 reported cases in 2025 compared to just 27 last year. Most infections are linked to travel to the Indian Ocean region, including India, Mauritius, and Sri Lanka. Chikungunya is a mosquito-borne virus that causes sudden fever and long-lasting joint pain, though it is rarely deadly. However, it can be dangerous for people with weakened immune systems or pre-existing health conditions, and it increases the risk of complications in newborns if the mother is infected. Globally, there have been over 240,000 cases reported this year alone. In the UK, two vaccines—Vimkunya and Ixchiq—are available through private travel clinics, but Ixchiq has faced controversy after two deaths were reported following its use in a mass vaccination program in La Reunion. As a result, UK health authorities have restricted its use in people over 65 while further investigations continue. Despite these concerns, experts predict Ixchiq may still generate higher sales than its competitor by 2031. If you’re planning to travel to high-risk areas, consult your pharmacist or doctor about the best protection options.